What is Genmab’s business strategy? Why does Genmab believe it can succeed?
Genmab’s focus is product development, thus our primary business plan is to create a portfolio of high quality therapeutic products and to maximize the value of our business by following a strategy of both in-house development and out-licensing of products. In this way Genmab retains a beneficial level of ownership of the commercial rights or profit-sharing opportunities for different products. We manage the risk inherent in drug development by building a broad portfolio of products with numerous antibodies in development in order to provide us with multiple opportunities to succeed. Genmab has access to targets for new therapeutic products through numerous partnerships and in-licensing agreements including collaborations with companies such as Roche, Amgen and GlaxoSmithKline.
